@article{fdi:010073995,
  title = {{H}epatitis {C} in {L}aos : a 7-year retrospective study on 1765 patients},
  author = {{P}aboriboune, {P}. and {V}ial, {T}homas and {S}itbounlang, {P}. and {B}ertani, {S}t{\'e}phane and {T}repo, {C}. and {D}eny, {P}. and {B}abin, {F}. {X}. and {S}teenkeste, {N}. and {P}ineau, {P}. and {D}eharo, {E}ric},
  editor = {},
  language = {{ENG}},
  abstract = {{H}epatitis {C} virus ({HCV}) is a global health concern, notably in {S}outheast {A}sia, and in {L}aos the presentation of the {HCV}-induced liver disease is poorly known. {O}ur objective was thus to describe a comprehensive {HCV} infection pattern in order to guide national health policies. {A} study on a group of 1765 patients formerly diagnosed by rapid test in health centres was conducted at the {C}entre of {I}nfectiology {L}ao {C}hristophe {M}erieux in {V}ientiane. {T}he demographic information of patients, their infection status (viral load: {VL}), liver function (aminotransferases) and treatments were analysed. {R}esults showed that gender distribution of infected people was balanced; with median ages of 53.8 for men and 51.6years for women (13-86years). {T}he majority of patients (72%) were confirmed positive ({VL}>50{IU}/m{L}) and 28% of them had high {VL} (>6log(10)). {A}bout 23% of patients had level of aminotransferases indicative of liver damage (>40{IU}/m{L}); but less than 20% of patients received treatment. {P}atients rarely received a second sampling or medical imaging. {T}he survey also showed that cycloferon, pegylated interferon and ribavirin were the drugs prescribed preferentially by the medical staff, without following any international recommendations schemes. {I}n conclusion, we recommend that a population screening policy and better management of patients should be urgently implemented in the country, respecting official guidelines. {H}owever, the cost of biological analysis and treatment are significant barriers that must be removed. {P}ublic health resolutions should be immediately enforced in the perspective of meeting the {WHO} {HCV} elimination deadline by 2030.},
  keywords = {{H}epatitis {C} virus ({HCV}) ; {HCV} incidence ; {A}ntiviral agents ; {L}aos ; {LAOS}},
  booktitle = {},
  journal = {{V}irologica {S}inica},
  volume = {33},
  numero = {4},
  pages = {295--303},
  ISSN = {1674-0769},
  year = {2018},
  DOI = {10.1007/s12250-018-0039-9},
  URL = {https://www.documentation.ird.fr/hor/fdi:010073995},
}